Forest Laboratories Inc.
Article Abstract:
Forest Laboratories Inc. has outperformed itsdrug industry peers during the past several years due to its product Celexa . Issue is top ranked for 2004 but encroachment of generics in the market will slow down earnings growth for the next 3 -5 years.
Publisher: Value Line Publishing, Inc.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2003
Marketing procedures, Marketing, Company marketing practices, Forest Laboratories Inc., FRX, Celexa (Medication)
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2003
User Contributions:
Comment about this article or add new information about this topic:
Pfizer Inc
Article Abstract:
Pfizer Inc. acquired Pharmacia making the combined entity a giant in the industry. Shares are top-quality with decent dividend yield, offering investors unparalleled stability and consistency with 3-5 year annual share-n et growth.
Publisher: Value Line Publishing, Inc.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2003
Acquisitions & mergers, Mergers, acquisitions and divestments, Company acquisition/merger, Pfizer Inc., PFE, Pharmacia Inc.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2003
User Contributions:
Comment about this article or add new information about this topic:
Subjects list: United States, Pharmaceutical industry, Finance, Company investment, Investments, Statistics, Securities, Company sales and earnings, Company earnings/profit, Company securities, Company business forecast/projection, Company forecasts
Similar abstracts:
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.